Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Equity (2020 - 2025)

Historic Return on Equity for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 1.04%.

  • Lyell Immunopharma's Return on Equity fell 7000.0% to 1.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.04%, marking a year-over-year decrease of 7000.0%. This contributed to the annual value of 0.65% for FY2024, which is 3400.0% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Return on Equity is 1.04%, which was down 7000.0% from 1.06% recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Return on Equity ranged from a high of 0.74% in Q1 2021 and a low of 1.06% during Q2 2025
  • Over the past 5 years, Lyell Immunopharma's median Return on Equity value was 0.26% (recorded in 2022), while the average stood at 0.37%.
  • Within the past 5 years, the most significant YoY rise in Lyell Immunopharma's Return on Equity was 3300bps (2022), while the steepest drop was -9900bps (2022).
  • Over the past 5 years, Lyell Immunopharma's Return on Equity (Quarter) stood at 0.22% in 2021, then rose by 2bps to 0.22% in 2022, then crashed by -52bps to 0.33% in 2023, then tumbled by -122bps to 0.73% in 2024, then tumbled by -42bps to 1.04% in 2025.
  • Its Return on Equity stands at 1.04% for Q3 2025, versus 1.06% for Q2 2025 and 0.94% for Q1 2025.